Systemic lupus erythematosus-related transverse myelitis (SLE-TM) is a rare but serious complication of SLE, which may result in significant morbidity. Its incidence is estimated between 0.5% and 1% of all SLE patients but may be the presenting feature in 30%–60% of these patients. Unfortunately, due to lack of high-quality studies, data regarding this condition remains limited. Its pathogenesis remains largely unknown and clinical presentation is variable. There are still no set guidelines regarding diagnosis, management, or monitoring and the role of autoantibodies remains controversial. In this review, we aim to summarize the available data regarding the epidemiology, pathogenesis, clinical features, management, and prognosis of this rare disease.
LiangMHCorzilliusMBaeSC, et al.The American College of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum1999; 42(4): 599–608.
3.
SarwarSMohamedASRogersS, et al.Neuropsychiatric systemic lupus erythematosus: a 2021 update on diagnosis, management, and current challenges. Cureus2021; 13(9): e17969.
4.
BehSCGreenbergBMFrohmanT, et al.Transverse myelitis. Neurol Clin2013; 31(1): 79–138.
5.
NikolopoulosDKitsosDPapathanasiouM, et al.Demyelinating syndromes in systemic lupus erythematosus: data from the “attikon” lupus cohort. Front Neurol2022; 13: 889613.
6.
ChessaEPigaMFlorisA, et al.Demyelinating syndrome in SLE: review of different disease subtypes and report of a case series. Reumatismo2017; 69(4): 175–183.
7.
WingerchukDMBanwellBBennettJL, et al.International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology2015; 85(2): 177–189.
8.
WangMWangZZhangL, et al.Exploring the risk factors and prognosis of transverse myelitis in systemic lupus erythematosus. Ther Adv Chronic Dis2022; 13: 20406223221097330.
9.
WilliamsJNSpeyerCBKrepsDJ, et al.Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. Lupus2019; 28(14): 1656–1662.
10.
WenXXuDYuanS, et al.Transverse myelitis in systemic lupus erythematosus: a case report and systematic literature review. Autoimmun Rev2022; 21(6): 103103.
11.
ZhangSWangZZhaoJ, et al.Clinical features of transverse myelitis associated with systemic lupus erythematosus. Lupus2020; 29(4): 389–397.
12.
ChiganerEHLessaCFdi PaceJL, et al.Transverse myelitis in systemic lupus erythematosus: clinical features and prognostic factors in a large cohort of Latin American patients. J Clin Rheumatol2021; 27(6S): S204–S211.
13.
MehtaPGuptaLMuhammedH, et al.Spectrum of myelitis in systemic lupus erythematosus: experience from a single tertiary care centre over 25 years. Mediterr J Rheumatol2021; 32(1): 31–38.
14.
AhnSMHongSLimDH, et al.Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus. Korean J Intern Med2019; 34(2): 442–451.
15.
HrybJPChiganerEContenttiEC, et al.Myelitis in systemic lupus erythematosus: clinical features, immunological profile and magnetic resonance imaging of five cases. Spinal Cord Ser Cases2016; 2: 16005.
16.
SaisonJCostedoat-ChalumeauNMaucort-BoulchD, et al.Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. Lupus2015; 24(1): 74–81.
17.
KatsiariCGGiavriIMitsikostasDD, et al.Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. Eur J Neurol2011; 18(4): 556–563.
18.
EspinosaGMendizábalAMínguezS, et al.Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum2010; 39(4): 246–256.
19.
BirnbaumJPetriMThompsonR, et al.Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum2009; 60(11): 3378–3387.
20.
D’CruzDPMellor-PitaSJovenB, et al.Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol2004; 31(2): 280–285.
21.
KovacsBLavertyTLBrentLH, et al.Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis2000; 59(2): 120–124.
22.
KrishnanCKaplinAIDeshpandeDM, et al.Transverse myelitis: pathogenesis, diagnosis, and treatment. Front Biosci2004; 9: 1483–1499.
23.
LiuYTuZZhangX, et al.Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: a review. Front Cell Dev Biol2022; 10: 998328.
24.
George-ChandyATrysbergEErikssonK. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther2008; 10(4): R97.
25.
SciasciaSBertolacciniMLRoccatelloD, et al.Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review. J Neurol2014; 261(9): 1706–1714.
26.
PröbstelAKThaneiMErniB, et al.Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. Rheumatology (Oxford)2019; 58(5): 908–913.
27.
LavalleCPizarroSDrenkardC, et al.Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol1990; 17(1): 34–37.
28.
TonoTNagaiTHoshiyamaT, et al.Transverse myelitis extended to disseminated encephalitis in systemic lupus erythematosus: histological evidence for vasculitis. Mod Rheumatol2016; 26(6): 958–962.
29.
AndrianakosAADuffyJSuzukiM, et al.Transverse myelopathy in systemic lupus erythematosus. Report of three cases and review of the literature. Ann Intern Med1975; 83(5): 616–624.
BertsiasGKIoannidisJPAAringerM, et al.EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis2010; 69(12): 2074–2082.
32.
Neumann-AndersenGLindgrenS. Involvement of the entire spinal cord and medulla oblongata in acute catastrophic-onset transverse myelitis in SLE. Clin Rheumatol2000; 19(2): 156–160.
33.
RheuCWLeeSIYooWH. A catastrophic-onset longitudinal myelitis accompanied by bilateral internuclear ophthalmoplegia in a patient with systemic lupus erythematosus. J Korean Med Sci2005; 20(6): 1085.
34.
BarnesGBenjaminSBowenJD, et al.Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurol2002; 59(4): 499–505.
35.
FarinaNAbdulsalamRMcDonnellT, et al.Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events. Rheumatology (Oxford)2023; 62(6): 2252–2256.
36.
KimJHLeeSIParkSI, et al.Recurrent transverse myelitis in primary antiphospholipid syndrome - case report and literature review. Rheumatol Int2004; 24(4): 244–246.
PapachristosDAOonSHanlyJG, et al.Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum2021; 51(1): 49–71.
42.
Barile-FabrisLAriza-AndracaROlguín-OrtegaL, et al.Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis2005; 64(4): 620–625.
43.
StojanovichLStojanovichRKostichV, et al.Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus2003; 12(1): 3–7.
44.
LuXGuYWangY, et al.Prognostic factors of lupus myelopathy. Lupus2008; 17(4): 323–328.
45.
TavorYHerskovitzMRonenG, et al.Longitudinally extensive transverse myelitis in a lupus–neuromyelitis optica overlap. Rambam Maimonides Med J2021; 12(1).
46.
TakeiKSatoMNakamuraM, et al.Case report: longitudinally extensive transverse myelitis with anti-NMDA receptor antibodies during a systemic lupus erythematosus flare-up. BMJ Case Rep2015; 1–4.
47.
NardoneRFitzgeraldRTBaileyA, et al.Longitudinally extensive transverse myelitis in systemic lupus erythematosus: case report and review of the literature. Clin Neurol Neurosurg2015; 129: 57–61.
48.
SeyedaliSAlpertDR. Case Report: longitudinal extensive transverse myelitis: a rare neurological complication of systemic lupus erythematosus. BMJ Case Rep2019; 12(4): e228950.
49.
LindblomJMohanCParodisI. Biomarkers in neuropsychiatric systemic lupus erythematosus: a systematic literature review of the last decade. Brain Sci2022; 12(2): 192.
50.
VanarsaKSasidharanPDuranV, et al.Aptamer-based screen of neuropsychiatric lupus cerebrospinal fluid reveals potential biomarkers that overlap with the choroid plexus transcriptome. Arthritis Rheumatol2022; 74(7): 1223–1234.
51.
MancaE. Autoantibodies in neuropsychiatric systemic lupus erythematosus (NPSLE): can they Be used as biomarkers for the differential diagnosis of this disease. Clin Rev Allergy Immunol2022; 63(2): 194–209.
52.
WangXFengDKeY, et al.Brain-reactive antibodies are potential biomarkers for evaluating therapeutic efficacy in NPSLE patients. Neuropsychiatr Dis Treat2022; 18: 1329–1340.
53.
PlüßMTampeBNiebuschN, et al.Clinical efficacy of routinely administered Belimumab on proteinuria and neuropsychiatric lupus. Front Med (Lausanne)2020; 7: 222.
54.
XieBDuKHuangF, et al.Cationic nanomaterials for autoimmune diseases therapy. Front Pharmacol2022; 12: 762362.
55.
FanYLiuXWuJ, et al.Small molecule compound K-7174 attenuates neuropsychiatric manifestations in lupus-prone mice. Brain Res2023; 1801: 148203.
